Lilly's Retatrutide Tops Ozempic Head-to-Head in Type 2 Diabetes
- Lilly's Phase 3 TRANSCEND-T2D-2 pitted triple-agonist retatrutide against Ozempic 2 mg in roughly 1,300 adults with type 2 diabetes over 80 weeks, and hit its primary and key secondary endpoints.
- Both retatrutide doses cut A1C more than Ozempic and produced about twice the weight loss; the top dose carried more side effects and discontinuations.
- The trial was open-label and the data are company topline; Lilly plans regulatory filings in early 2027.
💡 Points Based on public reports
A head-to-head win over the diabetes market's reference product is the evidence payers and prescribers have been waiting for, and it lands on Novo's home turf rather than in obesity. The tolerability gap at the top dose is the caveat to watch: if dropouts hold up in full data, the 9 mg dose may be the commercial workhorse.
Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetes ↗